Keywords: final, results, 1st, ph, iii, antril, trial

FINAL RESULTS OF 1ST PH III ANTRIL TRIAL

Article | 20 June 1994

Synergen's recombinant human interleukin-1 receptor antagonist Antril (rhIL-1ra) does not significantly increase survival time in sepsis patients compared to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing